Boulder biotech Nivalis sees shares rise in IPO

Stock in bIotech drug developer Nivalis Therapeutics Inc. jumped 6.5 percent on its first day of public trading Wednesday, closing at $14.92 per share. The Boulder-based company generated $77 million from sales of 5.5 million shares in its IPO. Nivalis stock (Nasdaq: NVLS) debuted at $14 and rose as high as $17.89 in mid-day trading before settling to its closing price. The company, formerly N30 Pharmaceuticals, is developing a cystic fibrosis treatment as its leading project. It plans to use…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news